Vir Biotechnology, Inc.
VIRVir Biotechnology is a clinical-stage biopharmaceutical company dedicated to developing medicines for serious infectious diseases and cancer.
Earnings
Next report
Aug 5, 2026 (In 1 week)Revenue estimate$135.9M
EPS estimate$0.33
Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Vir Biotechnology is a clinical-stage biopharmaceutical company dedicated to developing medicines for serious infectious diseases and cancer. The company leverages its deep understanding of immunology and proprietary technology platforms to engineer therapies that enhance the immune system's ability to overcome evasion tactics used by viruses and tumors.
Competitive position
A clinical-stage innovator utilizing proprietary AI-driven antibody discovery and licensed masking technologies to address high unmet medical needs.
GeographiesGlobal
Customer segmentsPatients, Healthcare systems
Business modelR&D intensive, IP licensing
SuppliersAI and machine learning infrastructure, Protein engineering technology, Clinical trial investigators, Contract manufacturing organizations
CustomersSpecialty pharmacies, Hospitals, Biopharmaceutical partners
CountryUnited States of America
Listed2019
Employees587.0
CEOMarianne De Backer
SectorHealthcare
IndustryBiotechnology
Websitevir.bio
FilingsSEC EDGAR
Questions, answered.
- What is Vir Biotechnology, Inc.'s market cap?
- Vir Biotechnology, Inc. (VIR) has a market capitalization of $1.5B and trades on NASDAQ.
- What is Vir Biotechnology, Inc.'s revenue and profitability?
- Vir Biotechnology, Inc. generated $65.5M in trailing twelve-month revenue with a net loss of $442.7M, representing a net margin of -676.0%. Gross margin stands at 96.1%, with free cash flow of -$449.6M. These figures are based on the Q1 2026 filing.
- Who are Vir Biotechnology, Inc.'s competitors?
- Vir Biotechnology, Inc.'s key competitors include Gilead Sciences, Inc., Amgen Inc., Regeneron Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
- Who does Vir Biotechnology, Inc. partner with?
- Vir Biotechnology, Inc.'s notable partners include Sanofi, Amunix Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and others.
- Where is Vir Biotechnology, Inc. headquartered?
- Vir Biotechnology, Inc. is headquartered in United States of America and employs approximately 587 people. It has been publicly traded since 2019.
